Many cases of breast cancer show loss of estrogen receptor (ER) a expression, which leads to unresponsiveness to antihormonal treatment even though there is no loss of the structurally and biochemically similar ER b. ER activity is positively and negatively regulated by transcriptional regulators such as histone deacetylase (HDAC), which is known to be a negative ER regulator. Here, we evaluated using ER b as an alternative target for tamoxifen therapy by treating ER a-negative, b-positive breast cancer cells with the HDAC inhibitor trichostatin A (TSA), and testing whether tamoxifen responsiveness increased following upregulation of ER b. TSA enhanced the overall ER transcriptional activity in these cells, as visualized by estrogen response element-regulated reporter and the expression of progesterone receptor, a known ER target, without ER a restoration. Additionally, TSA induced the expression and nuclear translocation of ER b but not a, suggesting that these actions leading to increase of ER transcriptional activity are mediated through ER b rather than a. Furthermore, following treatment with TSA, the formerly unresponsive MDA-MB-231 and Hs578T breast cancer cells became responsive to tamoxifen. However, reduction of ER b expression by short interfering RNA abrogated this TSA-induced sensitization effect in these cells. Together, these results show that the HDAC inhibitor TSA sensitized ER a-negative, antihormone-unresponsive breast cancer cells to tamoxifen treatment possibly by upregulating ER b activity.
Introduction
Estrogen is a key regulator for normal growth and differentiation in the mammary glands, reproductive organs and bones (Hedden et al., 1995; Jordan, 2001; Park and Jordan, 2002) , and also for the malignant progression of breast and endometrial cancers (Kaaks et al., 2002) . All normal and malignant biological effects of estrogen are mediated by two distinct estrogen receptors (ERs), a and b, that belong to the nuclear receptor superfamily and function as transcription factors, suggesting that ERs play an important role in the control of growth and apoptosis of normal and tumor cells. Both ERs have highly homologous ligand-binding and DNA-binding domains, and two similar activation function sites (Nilsson and Gustafsson, 2000) that are important in interactions with nuclear receptor coactivators (Acevedo and Kraus, 2003) or corepressors (Jung et al., 2001; Shi et al., 2001; Kumar et al., 2002) . Although they are highly similar in some regards, ER a and b exhibit differences in their cellular distributions (Palmieri et al., 2002) , responses to hormones (Paech et al., 1999) , spectrums of target promoters (Levenson et al., 2002) , and even in possessing opposing activation and repression activities in the same cellular/promoter context (Liu et al., 2002) . ER b is a less efficient activator, and may repress or even inhibit ER a (Hall and McDonnell, 1999) , although ER b often activates the same target promoters as are activated by ER a.
Interactions between ERs and coactivators allow recruitment of histone acetyl transferases (HATs) (Kim et al., 2001 , Sun et al., 2001 Fan et al., 2002; McDonnell and Norris, 2002; Yanagisawa et al., 2002) , which acetylate histones and lead to induction of transcription. In contrast, interactions between ERs and corepressors recruit histone deacetylases (HDACs) (Jung et al., 2001; Mazumdar et al., 2001; Shi et al., 2001; Sun et al., 2001; Kumar et al., 2002; McDonnell and Norris, 2002) , which switch off transcription by removing the acetyl groups from the histones. In this way, transcriptional up-and downregulation by ERs involves the recruitment of histone-modifying enzymes (HAT and HDAC) by protein-protein interactions with diverse coactivators and corepressors (Jung et al., 2001; Kim et al., 2001; Mazumdar et al., 2001; Shi et al., 2001; Sun et al., 2001; Fan et al., 2002; Kumar et al., 2002; McDonnell and Norris, 2002; Yanagisawa et al., 2002) . Therefore, the transcriptional activities of ER a and b are determined by the integrated activities of all the transcriptional regulators associated with ER a or b that are assembled at the various target promoters. Their transcriptional activities are implicated in gender-related prostate and breast cancers via regulating the proliferative effect of estrogen mediated through ER a (Couse and Korach, 1999; Sun et al., 2001; Weihua et al., 2002) . In contrast, ER b plays a potential antiproliferative role by inhibiting the transcriptional activity of ER a (Jensen et al., 2001; Sun et al., 2001; Weihua et al., 2002) .
Antihormone such as tamoxifen (TAM), also known as selective estrogen receptor modifiers (SERMS), can modulate transcriptional activity of ER a and b (Hedden et al., 1995; Nilsson and Gustafsson, 2000; Jordan, 2001; Park and Jordan, 2002) for effective treatment of ER a-positive breast cancers (Hedden et al., 1995; Jordan, 2001; Park and Jordan, 2002) . Antihormone is believed to treat cancer by blocking the proliferative effect of estrogen through ER a, making the presence of ER a, but not b, necessary for antihormone responsiveness. Although it is not clear why the highly similar ER a and b respond differently to hormone and antihormone, it might be at least partially due to dissimilarities in the regulation of their transcriptional activities Levenson et al., 2002; Liu et al., 2002) .
During breast cancer progression, many initially ER a-positive breast cancers lose ER a, and thus antihormone responsiveness (Chang et al., 2000; McDonnell and Norris, 2002; Powles, 2002) , via silencing of ER a gene by aberrant methylation of CpG islands in its promoter (Yang et al., 2000 (Yang et al., , 2001 Bovenzi and Momparler, 2001 ). Because ER a-negative, antihormone-unresponsive breast cancers are generally more aggressive and prone to relapse (Chang et al., 2000; Powles, 2002) , we need new therapies or strategies for sensitization of ER a-negative breast cancer cells to antihormonal treatment. To this end, we explored a new combinatory approach for sensitization of ER anegative breast cancer cells to the antihormone TAM. ER b, which functions as a repressor rather than an activator Liu et al., 2002) , is present at low levels in most sporadic breast cancers, including many that are ER a-negative (Bieche et al., 2001; Palmieri et al., 2002) . This led us to question whether modulation of ER b transcriptional activity might enhance the TAM response in ER a-negative, b-positive breast cancer cells. In this work, we report that enhancement of ER b activity by addition of an HDAC inhibitor can induce responsiveness to TAM in ER anegative breast cancer cells. Our study implies that modulation of transcriptional activity of ER b may provide a potential alternative target for ER a-negative breast cancers.
Results

HDAC inhibition upregulates the gross ER activity in ER a-negative breast cancer cells
To explore a new method for sensitizing ER a-negative breast cancer cells to antihormones, we attempted to employ ER b as a sensitization target. To do this, we used two cell lines (MDA-MB-231 and Hs578T) that express ER b but not a and the other two cell lines (MCF-7 and ZR75-1) that express both ER a and b (Yang et al., 2000; Bovenzi and Momparler (2001) ). ER b was expressed in all four breast cancer cells, without regard to ER a expression status, but the level of ER b expression in ER a-negative cells appeared to be higher than that in ER a-positive cells (Figure 1a) .
Based on the previous reports that ER b is an inefficient activator Liu et al., 2002) , and that HDAC is involved in negative regulation of ERs (Jung et al., 2001; Shi et al., 2001; Sun et al., 2001; Kumar et al., 2002; McDonnell and Norris, 2002) , we investigated whether HDAC inhibition by trichostatin A (TSA) treatment could modulate ER b activity. To do this, we evaluated the transcriptional activity of ERs by using a luciferase reporter construct driven by the estrogen response element (ERE), which is known to be regulated by ERs. MDA-MB-231 cells (ER a-negative, b-positive), MCF-7 cells (ER a-positive, b-positive) and HeLa cells (ER a-negative, b-negative) were transfected with the reporter constructs, and the transcriptional activities of endogenous ERs were measured. When MDA-MB-231 cells were treated with the HDAC inhibitor TSA, we observed a significant (B2-7-fold) increase in ERE-driven transcription, in a dose-dependent manner up to 165 nM, without addition of b-estradiol (b 2 ) or genistein ( Figure 1b) . Past this point, the induction effect declined gradually, indicating that optimal induction of the ERE transcription in MDA-MB-231 cells occurred following treatment with B165 nM TSA (Figure 1b) . Similar to this, addition of TSA also stimulated the ERE-driven transcription in the presence of b 2 (B5.5-fold) or genistein (B3.4-fold) (Figure 1c) , indicating that the induction by TSA in the presence of hormone was comparable to that in the absence of hormone (Figure 1b and c) . Taken together, these observations suggested that TSA can upregulate the ERE-driven transcription in MDA-MB-231 cells, without regard to hormone addition.
We next studied the effect of TSA on ER-regulated transcription in ER a-positive MCF-7 cells. TSA barely increased the ERE-dependent transcription of ER a-positive cells at 165 nM in the absence of b 2 (Figure 1d ), where the optimal induction of ERE-driven transcription had been seen in ER a-negative cells (Figure 1b) , or across the whole range of tested TSA concentrations (data not shown). Similar to no effect of hormones on the TSA-regulated ERE-driven transcription in MDA-MB-231 cells, addition of hormones barely affect that in either MCF-7 cells (data not shown). Taken together, these observations suggest that TSA can significantly upregulate the ER activity of ERE-driven transcription in ER a-negative MDA-MB-231 cells, but has little effect on ER activity on the ERE in ER a-positive MCF-7 cells.
The antihormone TAM is used in breast cancer therapy by acting as an antagonist against ER activity in ER a-positive cells, leading to inhibition of proliferative effects of ER a . To test the effect of TAM on ER activity upregulated by TSA in ER a-negative cells, we examined ERE-driven transcription in ER a-negative cells treated by TAM in combination with TSA. In ER a-negative cells, TAM suppressed the TSA-induced ERE promoter activity to approximately twofold of the basal level, which was an approximately 73% reduction of induction ( Figure 1c ). We found that in the ER a-positive breast cancer cells, TAM suppressed ERE promoter activity with or without TSA (Figure 1d ). These findings suggest that TAM functioned as an antagonist for the TSA-induced ERE promoter activity in ER a-negative cells in a manner similar to its action in ER a-positive cells.
It has been reported that HDACs are functionally associated with DNMT (Yang et al., 2000; Bovenzi and Momparler, 2001; Ghoshal et al., 2002; Macaluso et al., 2003) . We therefore investigated whether a DNMT inhibitor, 5-aza-2 0 -deoxycytidine (AZA), at concentrations from 200 nM to 3 mM could affect the basal or TSAinduced ER activity in ER a-positive or -negative cells. In contrast to the TSA results (Figure 1b) , we found that AZA did not regulate ERE-driven transcription in either MDA-MB-231 (Figure 1c ) or MCF-7 cells (Figure 1d ), suggesting that AZA does not modulate ER transcriptional activity, regardless of ER a status. In support of this, we found that AZA in combination with TSA exhibited effects comparable to those of TSA alone (Figure 1c) .
Expression of ER b upregulates ERE-driven transcription following HDAC inhibition, in ER a-negative, b-negative cells Based on our observation that HDAC inhibition increased ERE-driven transcription in ER a-negative, We tested also whether TSA affected ErbB2 expression in ER a-negative or -positive cells, since a recent study has shown its transcriptional repression by HDAC inhibition in ErbB2-expressing breast cancer cells (Scott et al., 2002) . TSA reduced ErbB2 expression in ER anegative Hs578T and ER a-positive MCF-7 cells (Figure 3a , bottom), indicating that TSA suppressed ErbB2 expression without regard to ER a expression. This result suggests that HDAC inhibition not only activates PR expression but also suppresses ErbB2 expression in ER a-negative cells.
Because the PR gene is a well-known downstream target of ER a and is strongly correlated with the expression of ER a, we studied whether the observed PR induction occurred because of a restoration of ER a by HDAC inhibition. In this regard, it has been recently reported that either TSA or AZA alone could weakly restore ER a expression, and that TSA in combination with AZA could synergistically reactivate ER a expression in ER a-negative MDA-MB-231 and Hs578T cells (Yang et al., 2000; Bovenzi and Momparler, 2001 ). Accordingly, we used RT-PCR to monitor ER a restoration by TSA with or without AZA, by comparing the level of restored ER a transcript with that of the basal ER a transcript from MCF-7 total RNA. Unexpectedly, no ER a was detected in either MDA-MB-231 cells (Figure 3a ) or Hs578T cells (data not shown), after 1-4 days treatment with 82.5 nM TSA or 1 day treatment with 165 nM TSA, even though these conditions were sufficient to restore PR expression ( Figure 3a ) and activate ER reporter activity in the same cells (Figure 1b and c). Thus, it is possible that the upregulation of overall ER activity without ER a restoration may be sufficient for the PR restoration. Since previous studies have shown ER a restoration We next examined whether ER b could activate transcription of the PR gene, in order to determine whether PR restoration by TSA could be mediated through ER b in the absence of ER a. PR expression was measured in the presence of ER a or b by transfecting HeLa cells (which have no endogenous ER a or b; Figure 1a ) with V5-ER a or b cDNA expression vectors. PR expression was activated in the presence of ER a without regard to TSA treatment (Figure 3c) , consistent with the well-established close regulation of PR expression by ER a. However, in support of our hypothesis, ER b activated PR expression in the presence of TSA treatment but not in the absence of TSA treatment (Figure 3c ). TSA alone without the addition of exogenous ER a or b did not affect PR expression (Figure 3c ). These data suggest that ER b can activate PR expression, following TSA treatment.
If this is the case, ER b should be recruited to the PR promoter and may therefore activate its expression in response to TSA treatment. To determine whether ER b can be interacting with PR promoter, we performed chromatin immunoprecipitation (ChIP) assay by immunoprecipitating V5-ER b. In the absence of TSA, ER a but not b was located at the PR promoter (Figure 3d ). TSA treatment induced ER b to be located at the PR promoter, while it did not affect the ER a location at PR promoter and thus ER a was still interacting and stayed in HeLa or 293T cells transfected with V5-ER a or b cDNA expression vectors (Figure 3d or data not shown). The TSA-induced ER b recruitment to PR promoter was in good agreement with induction of PR expression by ER b following TSA treatment. Taken together, these results suggest that PR restoration by HDAC inhibition may be mediated through ER b in ER a-negative cells, consistent with enhancement of ERE-driven transcription induced by HDAC inhibition.
Upregulation of ER activity by HDAC inhibition in ER a-negative cells is mediated through an increase in ER b expression or nuclear translocation
Since it was unclear how ER b activity was upregulated by TSA in ER a-negative cells without ER a restoration, we examined the possibility of increased expression or subcellular localization of ER b. We found that in ER a-negative cells, the endogenous ER b transcript increased following treatment with TSA, although ER a was not restored (Figure 3a) . Additionally, both endogenous ( Figure 3b ) and exogenous ER b proteins (Figure 3c ) increased in the ER a-negative cells following TSA treatment, indicating that the ER b proteins increased with TSA in a promoter-independent manner and at a post-transcriptional level. Similarly, the exogenously expressed ER a proteins increased with TSA treatment (Figure 3c) . However, the endogenous ER a proteins ( Figure 3b ) and its endogenous transcripts ( Figure 3a) decreased following TSA treatment, indicating that TSA may regulate ER a expression primarily at the transcriptional level. These findings together suggest that TSA induces increased ER b protein expression at both the transcriptional and posttranscriptional levels, but that it induces ER a proteins at the post-transcriptional level, but represses them at the transcriptional level, leading to an apparent reduction in ER a proteins following TSA treatment. This suggests that a TSA-induced increase of ER b expression may enable the ER a-negative cells to upregulate ER activity and become sensitive to TAM.
Because nuclear translocation of many steroid hormone receptors can regulate their transcriptional activities (Hager et al., 2000; Kawata, 2001; Matsuda et al., 2002) , we investigated whether TSA can affect the subcellular distribution of ER b. Immunofluorescence staining of exogenous ER a and b revealed that ER b was primarily localized in the cytoplasm (Figure 4a-c  and g-i) , while ER a was predominantly in the nucleus (Figure 4m-o) . Intriguingly, ER b shuttling between the cytoplasm and nucleus allowed its nuclear localization after TSA treatment (Figure 4d -f and j-l), suggesting that TSA may regulate acetylation/deacetylation of ER b or (and) some protein(s) involved in its subcellular localization, and presumably ER b conformational change, resulting in shuttling of ER b into the nucleus. However, the nuclear localization of ER a appeared to be unaffected by TSA treatment (Figure 4p and r) . These indicate that TSA induced translocation of ER b from the cytoplasm to nucleus, leading to enhancement of ER b transcriptional activity.
To determine whether the TSA-induced ER b nuclear translocation could be affected by hormone or antihormone, we assessed the cellular localization of liganded and unliganded ER b in the presence of TSA. The unliganded ER b appeared to be translocated in the nucleus by TSA treatment (Figure 4a-f) . Also, the ER b liganded with hormone (b 2 or genistein seen in Figure  4g -l or data not shown, respectively). However, the ER b liganded with antihormone TAM (Figure 4s-x) was seen in the cytoplasm of some cells and also in the nucleus of some cells in the presence of TSA, indicating that TAM may partially inhibit the nuclear translocation or/and stay of ER b. Taken together, these data suggest that TSA treatment can induce the translocation of unliganded as well as hormone-liganded ER b. Together, these findings suggest that the underlying mechanism for TSA-induced activation of ER activity in ER a-negative cells may be related to upregulation of both expression and nuclear translocation of ER b.
HDAC inhibition by TSA sensitizes ER a-negative breast cancer cells to the antihormone TAM On the basis of our observations that HDAC inhibition by TSA led to TAM-antagonizable upregulation of ER activity in ER a-negative breast cancer cells, we next investigated whether this could be functionally linked to antihormone responsiveness. As an initial optimization step, we determined that TAM treatment dose of 2.5 mM exhibited little cytotoxic effect on either ER a-negative or antihormone-responsive ER a-positive breast cancer cells ( Figure 5 ). Next, we examined TSA dose response (Figure 5a ) and time course (data not shown) at a concentration range of 41.25 nM to 1 mM, for 1-4 days, and determined the relative upregulation of ER activity (Figures 1b, c and 2 ) and restoration of PR expression (Figure 3a and c) . Following this, we tested combinatory treatments. We found that treatment with TSA made ER a-negative MDA-MB-231 cells responsive to TAM (Figure 5a ). The maximal sensitization effect was achieved by combinatory treatment of 2.5 mM TAM with TSA at 165-330 nM for 1-2 days. Under these conditions, cell proliferation was inhibited by about 60.3%, as compared to 6.1 or 1.3% inhibition by TSA or TAM alone, respectively (Figure 5a ). In combination with 165 nM TSA showing the optimal sensitization effect, TAM dose response was next examined at a concentration range of 0.1-5 mM. The maximal sensitization effect was achieved by cotreatment of 165 nM TSA with 0.1-2.5 mM TAM for 1-2 days (Figure 5a ). We determined 165 nM TSA and 2.5 mM TAM for the cotreatment condition by considering maximal cytotoxic effect, maximal sensitization effect and the least cytotoxic effect of TAM and TSA.
We tested also whether its active metabolite 4-hydroxy-tamoxifen (OHT) could synergize with TSA in ER a-negative breast cells. To this end, OHT dose response was assessed at a concentration range of 0.1-2.5 mM in combination with 165 nM TSA. The sensitization effect was seen across all tested range and the maximal sensitization was achieved with 1 mM OHT (Figure 5a , bottom panel). The maximal growth inhibition effect of OHT (B79.1%) was higher than that of TAM (B60.3%), and the sensitization effect of OHT (B71-fold) was higher than that of TAM (B51-fold), at the lower concentration (1 mM of OHT and 2.5 mM of TAM). These findings suggest that OHT has the higher sensitization effect and its cotreatment with TSA can sensitize ER a-negative breast cells at lower concentrations.
Additionally, this synergistic cytotoxic effect of TSA and TAM was not seen following combinatory treatment with TAM and either AZA alone or TSA and AZA together (Figure 5b ) that did not affect ER transcriptional activity (Figure 1c and d) . These conditions showed additive effects (Figure 5b ) in the ER a-negative breast cancer cells, rather than a synergistic effect, further indicating that TAM sensitization requires upregulation of ER transcriptional activity in ER a-negative breast cancer cells. Consistent with no effect of hormones on TSA-induced upregulation of ERE-driven transcription results, the sensitization effect of TSA and TAM also occurred in the presence of hormone (DMEM supplemented with fetal bovine serum, or phenol red-free DMEM supplemented with charcoal stripped serum and hormone) and in the absence of hormone (phenol red-free DMEM supplemented with charcoal stripped serum but not hormone; data not shown), indicating that cotreatment of TAM with TSA can induce responsiveness to TAM in ER a-negative breast cancer cells, regardless of hormone status. In ER a-positive MCF-7 cells, in which the ER transcriptional activity was not affected by TSA, no synergistic effect was observed for any treatment combination (Figure 5c ). TSA treatment did not significantly induce the ER transcriptional activity of MCF-7 cells, and consequently did not enhance sensitivity of MCF-7 cells to TAM, unlike ER a-negative breast cancer cells MDA-MB-231. To further explore whether TSA-induced TAM sensitivity is a general phenomenon in ER a-negative breast cell lines, we evaluated the synergistic effect of TAM cotreatment with TSA in another ER a-negative breast cell line, Hs578T. In a manner similar to that seen in MDA-MB-231 cells, TSA enhanced the cytotoxic effect of TAM on Hs578T cells (Figure 5d ), suggesting that the synergistic effect of the HDAC inhibitor with TAM may be general to ER a-negative breast cancer cells. In another ER a-positive breast cancer cell line, ZR75-1, no sensitization effect was observed after combinatory treatment of TAM with TSA (Figure 5d ). Taken together, our experiments showed that the combined treatment of TAM with TSA could sensitize ER a-negative, but not ER a-positive, breast cancer cells to TAM.
We then further characterized the cell death in ER a-negative cells cotreated with TSA and TAM. With nucleus-specific diamidino-2-phenylindole (DAPI) staining, we observed more condensed nuclear morphology in MDA-MBA-231 cells cotreated with TSA and TAM when compared with those treated with TAM alone, suggesting that the combinatory treatment with TSA and TAM was more potently cytotoxic than that with TAM alone (Figure 5a , inset). The nuclear morphology of MDA-MBA-231 cells treated with TAM and TSA (Figure 5a , inset) was very analogous to that of MCF-7 treated with TAM (Figure 5c, inset) , indicating the TAM-induced cytotoxicity takes place similarly in both ER a-positive and -negative cells. We next investigated whether caspase 9 was activated during the cell death of MDA-MB-231 induced by cotreatment with TSA and TAM, as shown in the TAM-treated ER a-positive breast cancer cells. In MDA-MB-231 cells, procaspase 9 decreased slightly following treatment with TSA alone but not with TAM alone, and it was decreased further by TSA and TAM cotreatment (Figure 5b, inset) , in a similar manner as observed in the TAM-treated ER a-positive cells (Mandlekar and Kong, 2001) . Because activation of caspases is known to cleave PARP, we tested the PARP cleavage induced by antihormonal cell death triggered by sensitization of ER a-negative breast cells with TSA (Figure 5b, inset) . In the ER a-negative cells, PARP cleavage was highly augmented by TSA and TAM in combination, while it was not increased by TAM alone and was only weakly increased by TSA alone. Our findings suggest that a combinatory treatment with HDAC inhibitor and antihormone in ER anegative breast cells induces an apparent cell death similar to that in the TAM-treated ER a-positive breast cancer cells.
TAM responsiveness of ER a-negative cells following HDAC inhibition is mediated through ER b
The cytotoxic effect of TAM in combination with TSA was synergistic in the concentration range of 82.5-330 nM TSA in MDA-MB-231 cells (Figure 5a ). Interestingly, the sensitizing concentration range of TSA overlapped with the range of concentrations that induced the enhancement of overall ER transcriptional activity (Figures 1b, c, 2 and 3 ) regardless of ER a restoration. The result that AZA in combination with TAM had no synergistic effect on cytotoxicity was also consistent with the insignificant effect of AZA on the regulation of the ERE-driven transcription (Figures 1c,  d, 2 and 3 ). On this observed correlation between transcriptional activity and responsiveness, we next examined whether the sensitization of ER a-negative cells to TAM may be mediated through TSA-upregulated ER b activity. To do this, the synergistic effect of cotreatment with TAM and TSA was evaluated in ER anegative, b-negative HeLa cells, and its ER b stably expressing cells (HeLa þ ER b; Figure 6a , inset). TSA in combination with TAM inhibited proliferation by about 26% in HeLa cells, as compared to about 23.4 or 2.4% inhibition by TSA or TAM alone, respectively. This observation indicated TSA did not stimulate the cytotoxic effect of TAM on HeLa cells unlike MDA-MB-231 cells (Figure 6a ). However, TSA enhanced the cytotoxic effect of TAM on HeLa þ ER b cells by about 3.4-4-fold (Figure 6a) , in a manner similar to that seen in MDA-MB-231 cells (Figures 5a and b) , suggesting that expression of ER b in the formerly unresponsive ER a-negative, b-negative cells can induce antihormone responsiveness by inhibiting HDAC activity. In addition, the expression of ER b in HeLa cells activated the ERE-driven transcription and PR expression in the presence of TSA (Figures 2a, c and 3b) , indicating that upregulation of ER b activity by TSA may be mechanistically implicated in the synergistic effect of TSA on the responsiveness to TAM in HeLa þ ER b (Figure 6a) . In contrast to TSA, AZA in combination with TAM did not exhibit the sensitization effect on either HeLa cells or HeLa þ ER b (data not shown), indicating that AZA had no synergistic effect regardless of ER status. The cytotoxic effect of TAM in combination with TSA and AZA on either HeLa cells or HeLa þ ER b cells was comparable to that in combination with TSA alone (data not shown), further indicating that AZA had no synergistic effect. Also, HeLa cells expressing ER a were sensitive to TAM in a TSAindependent manner, in contrast to HeLa cells expressing ER b (data not shown), further supporting that the TSA sensitization effect may be mediated through ER b but not a.
To determine whether ER b can mediate the responsiveness to TAM in the presence of TSA in ER anegative breast cancer cells, we examined the effect of ER b short interfering RNA (siRNA) on the sensitivity to TAM. The sensitivity to TAM in the presence of TSA was measured in MDA-MB-231 cells transfected with siRNA of ER b. The knockdown of ER b by siRNA (Figure 6b , inset) rendered MDA-MB-231 cells unresponsive to TAM in response to TSA (Figure 6b ), indicating that the reduction of ER b expression abrogated the TSA-induced sensitization to TAM. Taken together, these observations suggested that ER b may mediate the synergistic effect of cotreatment with the HDAC inhibitor and TAM in the absence of ER a.
Discussion
Although current antihormonal therapeutics targeted at ERs are effective against ER a-positive breast cancer, there are few alternative approaches for treating the antihormone-unresponsive ER a-negative breast cancer cells. In this report, we explore a new strategy for sensitizing ER a-negative breast cancer cells to antihormones by combinatory treatment with an HDAC inhibitor. We found that ER a-negative breast cancer cells can be sensitized to TAM by combined treatment with TSA, suggesting that this new combinatory therapy could be effective in treating antihormone-unresponsive breast cancer patients.
For our study, we took advantage of the presence of ER b in ER a-negative breast cancer cells (Bieche et al., 2001; Palmieri et al., 2002) . Our findings demonstrated that HDAC inhibition activated ERE-luciferase reporter activities (Figure 1b and c) , and restored PR expression in the ER a-negative breast cancer cell lines MDA-MB-231 and Hs578T (Figure 3a) . This took place without detectable ER a restoration, suggesting that the modulation of ER transcriptional activity by the HDAC inhibitor in ER a-negative breast cancer cells is a bona fide regulation, not an artifact of the reporters (Figures  1-3) . TSA stimulated ERE-driven transcription and PR expression following expression of ER b but not a in ER a-negative, b-negative HeLa cells, indicating that the effect of TSA on upregulation of ER transcriptional activity may be dependent on the presence of ER b (Figures 2 and 3) . We additionally found that HDAC inhibition by TSA rendered the ER a-negative breast cancer MDA-MB-231 and Hs578T cells responsive to TAM, regardless of ER a restoration ( Figure 5 ). Moreover, the sensitization of the ER a-negative cells occurred quite coincidentally with increments in the gross ER transcriptional activity, implying the functional interplay between sensitization and transcriptional activity of ER (Figures 1b, c and 3) . We further demonstrated that the sensitization effect of TSA (Figures 5 and 6 ) was due to an upregulation of ER activity that was mostly correlated with upregulation of ER b expression (Figures 2 and 3) and/or nuclear translocation (Figure 4 ) rather than that of ER a (Figure 2b) . Furthermore, the stabilized expression of ER b in ER a-negative, b-negative HeLa cells induced antihormone responsiveness following treatment of TSA, indicating the potential role of ER b in the TSAinduced sensitivity to antihormone (Figure 6a ). In contrast, the reduced expression of ER b in MDA-MB-231 cells abrogated the antihormone responsiveness in the presence of TSA, supporting the mechanistic implication of ER b in the effect of TSA on sensitization to antihormone in ER a-negative cells (Figure 6b ). This correlation between ER b expression and TSA sensitization of ER a-negative cells provides a mechanistic basis for the role of ER b in TSA-induced TAM responsiveness in the absence of ER a.
Additionally, we found that HDAC inhibition affected ER a and b in different ways. Inhibition of HDAC only weakly enhanced ER a, while it markedly upregulated the expression and function of ER b (Figures 1-3) , and dramatically translocated ER b to nucleus (Figure 4) . We have determined two of the possible reasons why HDAC inhibition significantly affected ER b but not a activity. (i) HDAC inhibition quantitatively reduces the final ER a expression ( Figures  3a and b) , while it may qualitatively enhance ER a transcriptional activity, leading to no apparent effects on the gross ER a activity (Figures 1d and 2b) . Therefore, its gross activity may be similar before and after TSA treatment. (ii) TSA can translocate ER b from the cytoplasm to nucleus, whereas it does not affect the subcellular location of ER a (Figure 4) .
DNMT inhibition in ER a-negative cells is not very effective at restoring PR (Yang et al., 2000; Bovenzi and Momparler, 2001 ) and additionally, in our study, it did not affect reporter transcription activities driven by ERE element in ER a-negative cells. These raise the possibility that its inability to upregulate ER activity may render it unable to generate a good responsiveness to TAM in ER a-negative cells, unlike HDAC inhibition (Figures 1c and 3a) . This further supports that antihormonal sensitization of ER a-negative cells may require upregulation of ER activity.
The clear upregulation of ER activity without efficient ER a restoration led to speculation that the modulation of ER transcriptional activity by the HDAC inhibitor, TSA, in ER a-negative breast cancer cells was not dependent on the ER a restoration. Also, there was not a strong correlation observed between ER a and PR expression in TSA-treated ER a-negative breast cancer cells. Consistent with this, the optimal TAM sensitization of the ER a-negative breast cancer cells occurred without detectable ER a restoration, suggesting that ER a restoration might not be required for sensitization. Moreover, the experimental conditions for the optimal induction of ER activity and responsiveness to TAM with HDAC inhibition in ER a-negative breast cancer cells were inappropriate for the optimal ER a restoration that is induced with either higher doses of TSA or AZA alone, or both, for longer durations (Yang et al., 2000 (Yang et al., , 2001 Bovenzi and Momparler, 2001 ). Therefore, TSA-induced sensitization of ER a-negative breast cancer cells to TAM did not appear to require ER a restoration within the limits detectable by RT-PCR. Instead, we found that TAM sensitization by HDAC inhibition required ER b. Exogenous ER b could induce the upregulation of ERE-driven transcription (Figure 2 ) and PR expression in the presence of TSA to levels similar to those induced by exogenous ER a in HeLa cells that had no PR expression (Figure 2c ). Moreover, ER b could interact with the PR promoter following TSA treatment, as ER a did regardless of TSA. Therefore, the HDAC inhibition-mediated repressionactivation switch of ER activity in ER a-negative breast cancer cells seems to be largely dependent on ER b. However, it is possible that there may have been TSAinduced restoration of ER a at levels below the sensitivity of RT-PCR, and that the balance between ER a and b activity might be important for inducing PR restoration and the responsiveness to TAM.
Here we report a new method for sensitizing antihormonal-resistant ER a-negative breast cancer cells to antihormonal therapy by HDAC inhibition targeting ER b. Although additional animal and preclinical studies are required to evaluate the clinical effectiveness of combinatory treatment of antihormones with the HDAC inhibitor, it seems that this strategy may have important clinical applications. Upregulation of ER b activity and the resulting increase in the expression of PR and many other ER target genes may partially or temporally improve the clinical course of antihormonal therapy of ER a-negative breast cancer patients. As such, ER b upregulated by HDAC inhibition may be a potential target for treatment of ER a-negative breast cancers or prevention of recurrence, and we suggest that this new strategy be extensively explored.
Materials and methods
Cell cultures and treatment
The human breast cancer cell lines MDA-MB-231, Hs578T and ZR75-1 were grown in RPMI 1640 supplemented with 10% FBS, or phenol red-free DMEM containing 10% charcoal stripped serum with or without either 100 nM b 2 or 1 mM genistein. HeLa, 293T and MCF-7 were grown in DMEM supplemented with 10% FBS, or phenol red-free DMEM containing 10% charcoal stripped serum. Cells were grown in 24-well plates at a density of B2.5 Â 10 4 cells/well and allowed to grow for 24 h. Cells were then treated with single, double or triple drug combinations, using the HDAC inhibitorTSA (Sigma Chemical Co., St Louis, MO, USA) or the DNA methyltransferase (DNMT) inhibiting agent AZA (Sigma Chemical Co.), with or without TAM (Korea United Pharm. Inc.) or 4-OH TAM (Korea United Pharm. Inc.).
Plasmid constructs
To generate mammalian expression vectors for ER a (V5-ER a) and b (V5-ER b), cDNAs containing the entire open reading frame of each gene were produced by RT-PCR of MCF-7 mRNA using the following primers: ER a (5 0 -caccatgaccatgaccctccac-3 0 and 5 0 -gactgtggcagggaaaccctctgc-3 0 ); and ER b (5 0 -caccatggagatcaaaaactcaccgt-3 0 and 5 0 -ctgagactgtaggttctggg-3 0 ). The fragments were inserted into a pCDNA3.1 vector (Invitrogen) hooked to the V5 epitope (V5-pCDNA3.1).
Luciferase activity assay MCF-7, MDA-MB-231 or HeLa cells were washed and incubated in 24-well plates (except where otherwise indicated) in phenol red-free DMEM containing 10% charcoal stripped serum, 1 day before transfection. Transfections were performed in quadruplicate with the Effectene transfection kit (Qiagen), using 20 ng of ERE-luciferase reporter (Fan et al., 1999) and 2 ng of pRL CMV (Promega, Madison, WI, USA) to control for transfection efficiency. At 1 day after transfection, cells were incubated for another 24 h with or without 41.25 nM-5 mM TSA, 200 nM-3 mM AZA, or hormone (100 nM b 2 or 1 mM genestein) before being harvested and assayed using the Dual Luciferase Reporter Assay (Promega). HeLa cells were cotransfected with 1-200 ng of an empty V5-pCDNA3.1 vector, V5-ER a or V5-ER b, in addition to 20 ng EREluciferase reporter and 2 ng pRL CMV. The luciferase activity was standardized against the transfection efficiency for each sample.
RNA isolation and RT-PCR
Total RNA was isolated from cultured cells using the TRIzol reagent (Life Technologies, Inc., Grand Island, NY, USA) according to the manufacturer's instructions. RT-PCR was carried out using 3 mg of total RNA from transfected or nontransfected cells. The primer sequences for glyceraldehyde-6-phosphoate dehydrogenase (GAPDH; used as an invariant housekeeping gene internal control), ER a, b, PR and human erythroblastic leukemia viral oncogene homolog 2 (Her2/neu, ErbB2) are as follows: GAPDH (5 0 -gtcaacggatttggtctgtatt-3 0 , 5 0 -agtcttctgggtggcagtgat-3 0 ), ER a (5 0 -ggagacatgagacgtgccaa-3 0 , 5 0 -caccacgttcttgcacttca-3 0 ), ER b (5 0 -ctgttactggtccaggttca-3 0 , 5 0 -ccagctgatcatgtgtacca-3 0 ), PR (5 0 -gattcagaagccagccagag-3 0 , 5 0 -tgcctctcgcctagttgatt-3 0 ), ErbB2 (5 0 -gaaggtgaaggtgcttggatctgg-3 0 , 5 0 -tagctccccttggcaatctgc-3 0 ). RT-PCR was performed as follows: annealing at 551C with 30 cycles for ER a; annealing at 501C with 35 cycles for PR; annealing at 54.51C with 30 cycles for ER b; annealing at 651C with 33 cycles for ErbB2; and annealing at 551C with 15-20 cycles for GAPDH.
Immunoblotting MDA-MB-231 or HeLa cells were cotransfected with expression vectors for V5-ER a or b. After 2 days, cells were lysed in lysis buffer containing 17 mM Tris pH 8.0, 50 mM NaCl, 0.3% Triton X-100 and a protease inhibitor cocktail tablet (Boehringer Mannheim). V5-ER a and b were detected by immunoblotting with anti-V5-HRP (Invitrogen). Endogenous ER a or b was detected by anti-ER a (Neomarker) or b (Upstate). PARP and procaspase 9 were detected with anti-PARP and anti-procaspase 9 antibodies, respectively (PharMingen). Immunoreactive bands were normalized to that of the control anti-actin (Santa Cruz Biotechnology) band.
Chromatin immunoprecipitation assay
About 1 Â 10 6 HeLa or 293T cells were plated in 100 mm dish the day before transfection with V5-ER a or V5-ER b. The ChIP assay was performed with the anti-V5 antibody following treating the transfected cells with 100 nM b 2 or 165 nM TSA for 24 h (Noh and Lee, 2003) . The primer sequence for the PR promoter was as follows: (5 0 -GGCT TTGGGCGGGGCCTCCCTA-3 0 and 5 0 -TCTGCTGGCTCC GT ACTGCGG-3 0 ).
DAPI staining
After treatment with the designated drug(s) for 24 h, cells were stained with DAPI (Sigma). Nuclear morphology was observed under a fluorescence microscope (ZEISS).
Immunofluorescence confocal analysis
HeLa cells were plated and transfected with V5-ER a or b. At 1 day after transfection, cells were incubated for another 24 h with or without 165 nM TSA in combination with 100 nM b 2 , 1 mM genestein or 2.5 mM TAM. Cells were fixed with 3.7% formaldehyde for 10 min and incubated in the blocking solution (1% chicken egg albumin in 1 Â PBS containing 0.1% Tween 20) at room temperature for 30 min. Cells were incubated with anti-V5 (Invitrogen) for 1 h, and then incubated with the fluorescent antibody (Alexa Fluor568, Molecular Probes) in the dark for 1 h. DAPI staining was carried out as above. Cells were analysed under a confocal microscope (ZEISS).
MTT cell proliferation assay
The assay, based on the conversion of yellow tetrazolium salt MTT (Sigma) to purple formazan crystals by metabolically active cells, provides a quantitative determination of viable cells (Carmichael et al., 1987) by measuring the absorbance at 540 nm, following cell treatment with the designated drug(s) in triplicate. HeLa cell viability was evaluated with HeLa cell lines expressing V5-pCDNA3.1, V5-ER a or V5-ER b, which were transfected with V5-pCDNA3.1, V5-ER a or V5-ER b, selected with G418 (DUCHEFA), and screened by immunoblotting with anti-V5 antibody (Invitrogen).
Silencing of ER b by siRNA
The plasmid of siRNA for ER b (ER b siRNA) was generated by annealing two oligomers (5 0 -GATCCCCAACTCACCGTC GAGCCTTATTCAA GAGATAAGGCTCGACGGTGAGTT TTTTTGGAAA-3 0 and 5 0 -AGCTTTTCCAA AAAAACT CACCGTCGAGCCTTATCTCTTGAATAAGGCTCGACG GTGAGTTGGG-3 0 , shown in bold derived from the ER b sequences) and then inserting the annealed double-stranded oligomers into pSUPER (Brummelkamp et al., 2002) at BglII and HindIII sites. After transfecting MDA-MB-231 cells with ER b siRNA vector, silencing of ER b was confirmed by immunoblotting with anti-ER b antibody.
